Cipla Dividend: Last Day To Buy Shares To Qualify — Details Here
Shares of Cipla Ltd. will be of interest on Thursday, as the day marks the last session for investors to buy shares to qualify for receiving the dividend before the stock goes ex/record-date.
The record date determines the eligible shareholders who will receive the dividend payment. The ex-dividend date, which mostly coincides with the record date, marks when the share price adjusts to reflect the upcoming payout.
Cipla's board announced a final dividend of Rs 13 per share and a special dividend of Rs 3 for financial year 2025. The record date to determine the shareholders eligible for the dividend payout has been fixed as June 27.
The company in the last financial year gave a divided of Rs 16 in total. The total value of the dividend to be disbursed amounts to around Rs 1,292 crore.
Given India's T+1 settlement cycle, shares purchased on the record date (June 27 in this case) will not be eligible for the dividend payment. Therefore, investors who own shares by June 26 will be the beneficiaries.
In comparison, the company had given a final dividend of Rs 13 in August 2024 and Rs 8.50 in July 2023.
Cipla's consolidated net profit rose 30% year-on-year in the fourth quarter of the current financial year, beating analysts' estimates.
The drugmaker posted a consolidated bottom line of Rs 1,222 crore in the quarter-ended March, according to an exchange filing on Tuesday. That compares with the Rs 1,023-crore consensus estimate of analysts tracked by Bloomberg.
The company's revenue climbed 9% year-on-year to Rs 6,729.69 crore, whereas the earnings before interest, taxes, depreciation and amortisation increased by 17% to Rs 1,538 crore. The Ebitda margin expanded to 22.8% from 21.4%.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.